United States securities and exchange commission logo





                            July 21, 2021

       James Porter
       Chief Executive Officer
       Nuvalent, Inc.
       One Broadway, 14th Floor
       Cambridge, MA 02142

                                                        Re: Nuvalent, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed July 7, 2021
                                                            File No. 333-257730

       Dear Dr. Porter:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1 filed July 7, 2021

       Overview, page 1

   1.                                                   We note your response
to prior comment 4. Please revise the Summary to disclose your
                                                        plan to conduct an End
of Phase 1 meeting with the FDA.
       Intellectual Property, page 156

   2.                                                   We note your response
to prior comment 17. Please clarify the applicable jurisdictions for
                                                        your ErbB program.
 James Porter
FirstName  LastNameJames Porter
Nuvalent, Inc.
Comapany
July       NameNuvalent, Inc.
     21, 2021
July 21,
Page  2 2021 Page 2
FirstName LastName
Exhibits

3.       Please revise Article VI of your Form of Amended and Restated Bylaws
to clearly state
         that the Delaware Forum Provision will not apply to any causes of
action arising under the
         Securities Act or the Exchange Act, consistent with your disclosure on
page 91.
         Alternately, please provide reasonable assurance that you will make
future investors
         aware of the provision   s limited applicability by including such
disclosure in your future
         Exchange Act reports.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Franklin Wyman at 202-551-3660 or Kevin Vaughn at
202-551-3494 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Jeffrey Gabor at 202-551-2544 with any
other questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:      Sarah Ashfaq